Predictors of drug prescription in nursing home residents: results from the INCUR study.
Drugs
Frailty
Nursing homes
Older persons
Polypharmacy
Journal
Internal and emergency medicine
ISSN: 1970-9366
Titre abrégé: Intern Emerg Med
Pays: Italy
ID NLM: 101263418
Informations de publication
Date de publication:
Jan 2022
Jan 2022
Historique:
received:
11
05
2021
accepted:
04
09
2021
pubmed:
22
9
2021
medline:
22
4
2022
entrez:
21
9
2021
Statut:
ppublish
Résumé
Polypharmacy represents a major clinical and public health issue in older persons. We aimed to measure the prevalence of polypharmacy, and the main predictors of drug prescription in nursing home residents. Post hoc analyses of the "Incidence of pNeumonia and related ConseqUences in nursing home Residents" (INCUR) study were conducted. Polypharmacy was defined as the prescription of 5 or more drugs. A frailty index (FI) was computed according to the model proposed by Rockwood and Mitnitski using 36 health deficits, including diseases, signs, symptoms, and disabilities. Linear regression models were performed to identify the main predictors of the number of prescribed drugs. The INCUR study enrolled 800 patients (mean [SD] age 86.2 [4.1] years, 74.1% women). The mean number of medications prescribed at the baseline was 8.5 (SD 4.1). Prevalence of polypharmacy was found 86.4%. The mean FI was 0.38 (SD 0.10). A fully adjusted linear multivariate regression model found an inverse and independent association between age and number of prescribed drugs (beta - 0.07, 95% CI - 0.13, - 0.02; p = 0.005). Conversely, the FI was independently and positively associated with the number of medications (beta 4.73, 95% CI 1.17, 8.29; p = 0.009). The prevalence of polypharmacy is high among older persons living in nursing home. Age and FI are significantly associated with the number of drugs. The number of prescribed drugs tends to decrease with age, whereas a direct association with frailty is reported.
Identifiants
pubmed: 34546497
doi: 10.1007/s11739-021-02841-6
pii: 10.1007/s11739-021-02841-6
pmc: PMC8841335
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
165-171Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2021. The Author(s).
Références
Jokanovic N, Tan ECK, Dooley MJ et al (2015) Prevalence and factors associated with polypharmacy in long-term care facilities: a systematic review. J Am Med Dir Assoc 16:535.e1-535.e12. https://doi.org/10.1016/j.jamda.2015.03.003
doi: 10.1016/j.jamda.2015.03.003
Gnjidic D, Hilmer SN, Blyth FM et al (2012) Polypharmacy cutoff and outcomes: five or more medicines were used to identify community-dwelling older men at risk of different adverse outcomes. J Clin Epidemiol 65:989–995. https://doi.org/10.1016/j.jclinepi.2012.02.018
doi: 10.1016/j.jclinepi.2012.02.018
pubmed: 22742913
Saum K-U, Schöttker B, Meid AD et al (2017) Is Polypharmacy associated with frailty in older people? Results from the ESTHER cohort study. J Am Geriatr Soc 65:e27–e32. https://doi.org/10.1111/jgs.14718
doi: 10.1111/jgs.14718
Clegg A, Young J, Iliffe S et al (2013) Frailty in elderly people. Lancet 381:752–762
doi: 10.1016/S0140-6736(12)62167-9
Mitnitski AB, Mogilner AJ, Rockwood K (2001) Accumulation of deficits as a proxy measure of aging. Sci World J 1:323–336. https://doi.org/10.1100/tsw.2001.58
doi: 10.1100/tsw.2001.58
Veronese N, Stubbs B, Noale M et al (2017) Polypharmacy is associated with higher frailty risk in older people: an 8-year longitudinal cohort study. J Am Med Dir Assoc 18:624–628. https://doi.org/10.1016/j.jamda.2017.02.009
doi: 10.1016/j.jamda.2017.02.009
pubmed: 28396180
pmcid: 5484754
Onder G, Liperoti R, Fialova D et al (2012) Polypharmacy in nursing home in Europe: results from the SHELTER study. J Gerontol Ser A Biol Sci Med Sci 67A:698–704. https://doi.org/10.1093/gerona/glr233
doi: 10.1093/gerona/glr233
Demougeot L, Rolland Y, Gérard S et al (2013) Incidence and economical effects of pneumonia in the older population living in French nursing homes: design and methods of the INCUR study. BMC Public Health 13:861. https://doi.org/10.1186/1471-2458-13-861
doi: 10.1186/1471-2458-13-861
pubmed: 24044421
pmcid: 3851141
Palmer K, Villani ER, Vetrano DL et al (2019) Association of polypharmacy and hyperpolypharmacy with frailty states: a systematic review and meta-analysis. Eur Geriatr Med 10:9–36. https://doi.org/10.1007/s41999-018-0124-5
doi: 10.1007/s41999-018-0124-5
pubmed: 32720270
Searle SD, Mitnitski A, Gahbauer EA et al (2008) A standard procedure for creating a frailty index. BMC Geriatr 8:24. https://doi.org/10.1186/1471-2318-8-24
doi: 10.1186/1471-2318-8-24
pubmed: 18826625
pmcid: 2573877
Kim HA, Shin JY, Kim MH, Park BJ (2014) Prevalence and predictors of polypharmacy among Korean elderly. PLoS ONE 9:e98043. https://doi.org/10.1371/journal.pone.0098043
doi: 10.1371/journal.pone.0098043
pubmed: 24915073
pmcid: 4051604
Tjia J, Velten SJ, Parsons C et al (2013) Studies to reduce unnecessary medication use in frail older adults: a systematic review. Drugs Aging 30:285–307
doi: 10.1007/s40266-013-0064-1
Lindley RI (2012) Drug trials for older people. J Gerontol Ser A Biol Sci Med Sci 67A:152–157. https://doi.org/10.1093/gerona/glr065
doi: 10.1093/gerona/glr065
Holmes HM (2009) Rational prescribing for patients with a reduced life expectancy. Clin Pharmacol Ther 85:103–107
doi: 10.1038/clpt.2008.211
Bonaga B, Sánchez-Jurado PM, Martínez-Reig M et al (2018) Frailty, polypharmacy, and health outcomes in older adults: the frailty and dependence in albacete study. J Am Med Dir Assoc 19:46–52. https://doi.org/10.1016/j.jamda.2017.07.008
doi: 10.1016/j.jamda.2017.07.008
pubmed: 28899661
Herr M, Robine JM, Pinot J et al (2015) Polypharmacy and frailty: prevalence, relationship, and impact on mortality in a French sample of 2350 old people. Pharmacoepidemiol Drug Saf 24:637–646. https://doi.org/10.1002/pds.3772
doi: 10.1002/pds.3772
pubmed: 25858336
Fried LP, Tangen CM, Walston J et al (2001) Frailty in older adults: evidence for a phenotype. J Gerontol Ser A Biol Sci Med Sci 56:M146–M157. https://doi.org/10.1093/gerona/56.3.m146
doi: 10.1093/gerona/56.3.m146
Gutiérrez-Valencia M, Izquierdo M, Cesari M et al (2018) The relationship between frailty and polypharmacy in older people: a systematic review. Br J Clin Pharmacol 84:1432–1444
doi: 10.1111/bcp.13590
Woo J, Zheng Z, Leung J, Chan P (2015) Prevalence of frailty and contributory factors in three Chinese populations with different socioeconomic and healthcare characteristics. BMC Geriatr 15:163. https://doi.org/10.1186/s12877-015-0160-7
doi: 10.1186/s12877-015-0160-7
pubmed: 26652647
pmcid: 4675032
Zheng Z, Guan S, Ding H et al (2016) prevalence and incidence of frailty in community-dwelling older people: Beijing longitudinal study of aging II. J Am Geriatr Soc 64:1281–1286. https://doi.org/10.1111/jgs.14135
doi: 10.1111/jgs.14135
pubmed: 27321607
Gutiérrez-Valencia M, Izquierdo M, Lacalle-Fabo E et al (2018) Relationship between frailty, polypharmacy, and underprescription in older adults living in nursing homes. Eur J Clin Pharmacol 74:961–970. https://doi.org/10.1007/s00228-018-2452-2
doi: 10.1007/s00228-018-2452-2
pubmed: 29589065
Cesari M, Pérez-Zepeda MU, Marzetti E (2017) Frailty and multimorbidity: different ways of thinking about geriatrics. J Am Med Dir Assoc 18:361–364. https://doi.org/10.1016/j.jamda.2016.12.086
doi: 10.1016/j.jamda.2016.12.086
pubmed: 28279606
Guthrie B, McCowan C, Davey P et al (2011) High risk prescribing in primary care patients particularly vulnerable to adverse drug events: cross sectional population database analysis in Scottish general practice. BMJ 342:d3514–d3514. https://doi.org/10.1136/bmj.d3514
doi: 10.1136/bmj.d3514
pubmed: 21693525
Guthrie B, Makubate B, Hernandez-Santiago V, Dreischulte T (2015) The rising tide of polypharmacy and drug-drug interactions: population database analysis 1995–2010. BMC Med 13:74. https://doi.org/10.1186/s12916-015-0322-7
doi: 10.1186/s12916-015-0322-7
pubmed: 25889849
pmcid: 4417329
Dumbreck S, Flynn A, Nairn M et al (2015) Drug-disease and drug-drug interactions: systematic examination of recommendations in 12 UK national clinical guidelines. BMJ 350:h949. https://doi.org/10.1136/bmj.h949
doi: 10.1136/bmj.h949
pubmed: 25762567
pmcid: 4356453
Maclagan LC, Maxwell CJ, Gandhi S et al (2017) Frailty and potentially inappropriate medication use at nursing home transition. J Am Geriatr Soc 65:2205–2212. https://doi.org/10.1111/jgs.15016
doi: 10.1111/jgs.15016
pubmed: 28752589